Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy
Gothenburg, October 12, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that the PhD thesis of the company’s co-worker Jing Ma was awarded the best Swedish PhD thesis of the year within the field of gene and cell therapy for 2021 by the Swedish Society for Gene and Cell Therapy (SSGCT).Jing Ma’s PhD thesis describes the development of Elicera's iTANK-platform and the upcoming CAR T-cell study in treatment of B-cell